This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EDB scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EDB as well as the biological activity of IL2. IL2-L19 resulted in efficient regional control of disease progression, increased time to distant metastasis and evidence of effect on circulating immune cell populations. A strong inhibition of growth of established tumors was observed in syngeneic and orthotopic tumor models in mice. This immunocytokine was designed for treating Advanced solid tumors, Advanced pancreatic cancer, Metastatic melanoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-193 | Anti-Human Fibronectin Extra Domain-B Recombinant Antibody (Radretumab) | IF, IP, Neut, FuncS, ELISA, FC, ICC | [(scFv - heavy - kappa) - IGHE - CH4]2 |
TAB-071WM | Anti-Human FN1 Recombinant Antibody (CGS-1) | ELISA, WB | Human Antibody |
TAB-001CQ-F(E) | Anti-Human FN1 Recombinant Antibody Fab Fragment (MOR03255) | ELISA, BL, IHC | Human antibody |
TAB-002CQ-F(E) | Anti-Human FN1 Recombinant Antibody Fab Fragment (ME-4C) | ELISA, IHC | Human antibody |
TAB-071WM-F(E) | Anti-Human FN1 Recombinant Antibody Fab Fragment (CGS-1) | ELISA, WB | Human Antibody |
There are currently no Customer reviews or questions for ACFP-SH159. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.